These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7518341)

  • 1. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
    Pollack A; Zagars GK; Kavadi VS
    Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
    Pollack A; Zagars GK; el-Naggar AK; Terry NH
    Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.
    Zagars GK; Pollack A
    Radiother Oncol; 1997 Sep; 44(3):213-21. PubMed ID: 9380819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.
    Zagars GK; von Eschenbach AC
    Cancer; 1993 Jul; 72(2):538-48. PubMed ID: 7686443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
    Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
    J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
    Zagars GK; Pollack A
    Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
    Zagars GK; Pollack A
    Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.
    Zagars GK
    Int J Radiat Oncol Biol Phys; 1992; 23(1):47-53. PubMed ID: 1374065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
    Zagars GK; Pollack A; von Eschenbach AC
    Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PSA doubling time in prostate cancer relapsed after endocrine therapy].
    Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
    Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):584-8. PubMed ID: 10965743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
    Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
    J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.
    Gauwitz MD; Pollack A; el-Naggar AK; Terry NH; von Eschenbach AC; Zagars GK
    Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):821-8. PubMed ID: 8138434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
    Pollack A; Zagars GK; Kopplin S
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):13-20. PubMed ID: 7536720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.
    Sartor CI; Strawderman MH; Lin XH; Kish KE; McLaughlin PW; Sandler HM
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):941-7. PubMed ID: 9276358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
    Lee WR; Hanks GE; Hanlon A
    J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
    Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH
    Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate.
    Zagars GK
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):39-45. PubMed ID: 7690017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.